greeksoup/ stock research

Omeros Corp.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 16 November 2026: press release. Guidance figures: 2 lowered, 1 new, 1 kept. The quarter’s numbers.

Key takeaways

  • Gross revenue rose 29.6% quarter on quarter: YARTEMLEA gross revenue was $41.8 million, up $9.5 million or 29.6% from $32.2 million in the second quarter. Net revenue rose 26% to $35.9 million from $28.5 million. Source
  • Gross-to-net rose to 14.0%: The gross-to-net adjustment was 14.0%, up from 11.5% in the second quarter. Management attributed the increase to higher purchases by entities covered by the 340B program. Source
  • Negative European opinion after re-examination: In October 2026 the CHMP issued a negative opinion on the narsoplimab marketing application for TA-TMA, following re-examination of its June 2026 negative opinion. Source
  • GAAP net loss driven by derivative: GAAP net loss was $57.4 million, or $0.79 per share, including a $62.0 million non-cash loss tied to the 2029 Notes derivative. Second-quarter GAAP net income was $13.2 million. Source
  • Adjusted net income positive at $4.7 million: Excluding non-cash items, non-GAAP adjusted net income was $4.7 million, or $0.06 per share, compared with $1.8 million, or $0.02 per share, in the second quarter. Source
  • Operating cash flow positive at $13.3 million: The company generated positive operating cash flow of $13.3 million in the third quarter, following $4.1 million in the second quarter. Source
  • 2029 Notes repurchase closed in July: The company repurchased $30.5 million principal of 2029 Notes for $60.2 million plus $0.2 million accrued interest. About $40.3 million principal remains outstanding. Source

“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow,”

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
OMS527 inpatient trial enrollment start Sourcefirst quarter of 2027first quarter of 2027Lowered from by year-end 2026
Start of two YARTEMLEA studies (ARDS and pediatric TA-TMA prevention) Sourcelate 2026 or early 2027late 2026 or early 2027Lowered from by year-end 2026
Target enrollment per YARTEMLEA study Sourcenot statedapproximately 50 to 60 patients eachNew
OMS805 Phase 1b trial start Sourcelate 2027late 2027Kept
Novo transition services completion Sourcemid-2027mid-2027
Novo milestone eligibility Sourcenot statedmore than $1.8 billion; up to $100 million near-term

What changed from last quarter

  • Guidance lowered: Enrollment start for the OMS527 inpatient trial moved from year-end 2026 to the first quarter of 2027. Source
  • Guidance lowered: Start window for the two YARTEMLEA studies moved from year-end 2026 to late 2026 or early 2027. Source
  • New: A second negative EMA opinion on narsoplimab for TA-TMA was issued in October 2026, after re-examination of the June 2026 opinion. Source
  • New: NTAP status for YARTEMLEA became effective October 1, 2026, after CMS granted it in July. Source

Revenue, customers and gross-to-net

  • Gross revenue rose 29.6% quarter on quarter: YARTEMLEA gross revenue was $41.8 million, up $9.5 million or 29.6% from $32.2 million in the second quarter. Net revenue rose 26% to $35.9 million from $28.5 million. Source
  • Gross-to-net rose to 14.0%: The gross-to-net adjustment was 14.0%, up from 11.5% in the second quarter. Management attributed the increase to higher purchases by entities covered by the 340B program. Source
  • Customer base and outpatient use grew: Management said the rise in 340B purchases reflected a substantially larger customer base and more outpatient use of YARTEMLEA. Source
  • Growth continued into fourth quarter: Management said momentum continued into the fourth quarter, with YARTEMLEA revenues continuing to grow. Source
  • NORD named YARTEMLEA innovation award: In September 2026 the National Organization for Rare Disorders named Omeros a recipient of its 2026 Industry Innovation Award for YARTEMLEA. Source

Reimbursement and regulatory status

  • NTAP status effective October 1: NTAP status took effect October 1, 2026, giving eligible hospitals up to $287,079 added Medicare payment per inpatient case. Management noted no off-label TA-TMA treatment has an NTAP. Source
  • Transplant centers briefed on reimbursement: Management said it is helping transplant centers understand YARTEMLEA reimbursement advantages, and is working to expand TA-TMA access through international approvals and named-patient programs. Source
  • Negative European opinion after re-examination: In October 2026 the CHMP issued a negative opinion on the narsoplimab marketing application for TA-TMA, following re-examination of its June 2026 negative opinion. Source

“We see YARTEMLEA not simply as a TA-TMA drug, but as an endothelial injury drug with broad therapeutic potential.”

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer

Costs, operating result and net loss

  • Operating expenses rose to $30.6 million: Research and development plus selling, general and administrative expenses totaled about $30.6 million, up from $27.7 million in the second quarter. Source
  • Operating income turned positive: The company reported operating income of $4.5 million, compared with $0.1 million in the second quarter. Source
  • Interest income fell on Novo reimbursement: Interest and other income was $1.9 million, down from $4.6 million, because the second quarter included a Novo reimbursement for zaltenibart inventory. Source
  • GAAP net loss driven by derivative: GAAP net loss was $57.4 million, or $0.79 per share, including a $62.0 million non-cash loss tied to the 2029 Notes derivative. Second-quarter GAAP net income was $13.2 million. Source
  • Adjusted net income positive at $4.7 million: Excluding non-cash items, non-GAAP adjusted net income was $4.7 million, or $0.06 per share, compared with $1.8 million, or $0.02 per share, in the second quarter. Source

Cash, debt and share count

  • Cash and investments were $95.3 million: Cash and short-term investments were $95.3 million at September 30, 2026. The prior release reported $132.0 million at June 30, 2026. Source
  • Operating cash flow positive at $13.3 million: The company generated positive operating cash flow of $13.3 million in the third quarter, following $4.1 million in the second quarter. Source
  • 2029 Notes repurchase closed in July: The company repurchased $30.5 million principal of 2029 Notes for $60.2 million plus $0.2 million accrued interest. About $40.3 million principal remains outstanding. Source
  • Conversion shares cut to 6.5 million: Shares issuable on conversion of the 2029 Notes fell from 11.4 million to 6.5 million, and $8.6 million of scheduled interest payments were eliminated. Source
  • Potentially issuable shares down 5.8 million: Together with 843,000 shares repurchased at $11.70 in the first half, the note transactions reduced outstanding or potentially issuable shares by about 5.8 million year to date. Source

“Together with expected zaltenibart-related milestone payments from Novo, these revenues are driving the rest of our pipeline forward”

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer

Pipeline and Novo partnership

  • OMS527 nonclinical study for FDA: The company is running a nonclinical study requested by FDA before starting the inpatient OMS527 trial, after preclinical work found no drug-interaction or safety concerns. Source
  • T-CAT now in IND-enabling studies: The T-CAT antibody platform, aimed initially at multidrug-resistant organisms, is now in IND-enabling studies, according to management. Source
  • Oral MASP-2 candidate selection continues: In the MASP-2 small-molecule program, the company continues characterizing compounds to select an oral development candidate. Source

YARTEMLEA expansion and field team

  • Ten field education positions added: Ten field-based education positions were added across Market Development Manager and Medical Science Liaison teams, plus a clinical nurse educator team of six. Source
  • Other endothelial-injury indications assessed: Management is assessing further YARTEMLEA opportunities in indications involving endothelial injury, lectin pathway activation, or thrombo-inflammation. Source
  • Revenues fund indication expansion: Management said YARTEMLEA revenues are funding efforts to expand its indications. Source

Oncology platform

  • OMS805 showed superior efficacy in models: In animal and cell-line studies, OMS805 showed efficacy superior to standard-of-care AML treatments evaluated, independent of several common AML genetic mutations. Source
  • Primate study cut progenitors up to 99%: A February 2026 nonhuman primate study reported one course of OncotoX-AML reduced myeloid progenitor cells by up to 99%, with no observed safety signals. Source
  • OMS805 IND-enabling work underway: IND-enabling studies and manufacturing development for the initial clinical supply of OMS805 drug substance are underway. Source

Coming up, as management said on 16 November 2026

  • Two YARTEMLEA studies to start: Studies in hyperinflammatory ARDS and in prevention of TA-TMA in high-risk pediatric patients are expected to start in late 2026 or early 2027. Source
  • OMS527 trial enrollment in Q1 2027: Management expects to begin enrollment in the OMS527 inpatient clinical trial in the first quarter of 2027. Source
  • OMS1029 Phase 2 program to start: Management said the company expects to initiate the Phase 2 clinical program for OMS1029, its long-acting MASP-2 inhibitor, with no date given. Source
  • OMS805 Phase 1b trial in late 2027: The first-in-human Phase 1b trial of OMS805 is targeted to begin in late 2027. Source
  • Novo transition services end mid-2027: Omeros expects to complete transition services for Novo by mid-2027, performed at Novo's cost. Source
  • Medicare outpatient payment from January 2027: Management said Medicare outpatient reimbursement for 340B-acquired YARTEMLEA begins January 1, 2027. Source

Figures management reported

FigureReported
Research and development expense, third quarter 2026 Source$16,060 thousand
Cost of product sales, third quarter 2026 Source$826 thousand
Product sales, net, nine months 2026 Source$74,356 thousand
Research and development expense, nine months 2026 Source$43,216 thousand

Risks management discussed

  • Regulatory: Management noted the two YARTEMLEA studies depend on institutional review board and ethics committee approvals before they can start. Source

Earlier plans management reported on

  • On track: Management said Novo's zaltenibart is on track for Phase 3 trial initiation. Source
  • Met: Management said 340B participation increased as expected, reflecting customer base expansion and more outpatient use. Source
  • Not stated: The prior release expected enrollment in two YARTEMLEA studies by year-end 2026; the current release gives late 2026 or early 2027.
  • Not stated: The prior release expected enrollment in the OMS527 inpatient trial by year-end 2026; the current release gives the first quarter of 2027.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.